FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893892798> ?p ?o ?g. }

• W2893892798 endingPage "1719" @default.
• W2893892798 startingPage "1710" @default.
• W2893892798 abstract "Objectives To evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA). Methods Patients (2–19 years) entered two phase III studies and continued in the long-term extension (LTE) study. Efficacy assessments were performed every 3 months, including adapted JIA American College of Rheumatology (aJIA-ACR) criteria, Juvenile Arthritis Disease Activity Score (JADAS) and ACR clinical remission on medication criteria (CR ACR ). Efficacy analyses are reported as per the intent-to-treat population. Results 144 of the 177 patients (81%) enrolled in the core study entered the LTE. Overall, 75 patients (42%) completed and 102 (58%) discontinued mainly for inefficacy (63/102, 62%), with higher discontinuation rates noted in the late responders group (n=25/31, 81%) versus early responders (n=11/38, 29%). At 2 years, aJIA-ACR 50/70/90 response rates were 62%, 61% and 54%, respectively. CR ACR was achieved by 20% of patients at month 6; 32% at 2 years. A JADAS low disease activity score was achieved by 49% of patients at 2 years. Efficacy results were maintained up to 5 years. Of the 128/177 (72.3%) patients on glucocorticoids, 20 (15.6%) discontinued and 28 (22%) tapered to 0.150 mg/kg/day. Seven patients discontinued canakinumab due to CR. There were 13 macrophage activation syndrome (three previously reported) and no additional deaths (three previously reported). No new safety findings were observed. Conclusion Response to canakinumab treatment was sustained and associated with substantial glucocorticoid dose reduction or discontinuation and a relatively low retention-on-treatment rate. No new safety findings were observed on long-term use of canakinumab. Trial registration numbers NCT00886769 , NCT00889863 , NCT00426218 and NCT00891046 ." @default.
• W2893892798 created "2018-10-05" @default.
• W2893892798 creator A5006567240 @default.
• W2893892798 creator A5007608312 @default.
• W2893892798 creator A5009421355 @default.
• W2893892798 creator A5009557875 @default.
• W2893892798 creator A5015700716 @default.
• W2893892798 creator A5021386589 @default.
• W2893892798 creator A5025765870 @default.
• W2893892798 creator A5027612338 @default.
• W2893892798 creator A5029030825 @default.
• W2893892798 creator A5030599616 @default.
• W2893892798 creator A5039041675 @default.
• W2893892798 creator A5040230445 @default.
• W2893892798 creator A5041199022 @default.
• W2893892798 creator A5053719643 @default.
• W2893892798 creator A5053826746 @default.
• W2893892798 creator A5054508057 @default.
• W2893892798 creator A5055180780 @default.
• W2893892798 creator A5064426652 @default.
• W2893892798 creator A5068517463 @default.
• W2893892798 creator A5074351117 @default.
• W2893892798 creator A5079738832 @default.
• W2893892798 creator A5080140512 @default.
• W2893892798 creator A5085125040 @default.
• W2893892798 creator A5086450412 @default.
• W2893892798 creator A5087563280 @default.
• W2893892798 date "2018-09-29" @default.
• W2893892798 modified "2023-10-18" @default.
• W2893892798 title "Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials" @default.
• W2893892798 cites W138522404 @default.
• W2893892798 cites W1685776505 @default.
• W2893892798 cites W1779387069 @default.
• W2893892798 cites W1903167817 @default.
• W2893892798 cites W1969936299 @default.
• W2893892798 cites W1987733166 @default.
• W2893892798 cites W1998366883 @default.
• W2893892798 cites W2004149792 @default.
• W2893892798 cites W2017213437 @default.
• W2893892798 cites W2021579922 @default.
• W2893892798 cites W2024714476 @default.
• W2893892798 cites W2026404803 @default.
• W2893892798 cites W2028698702 @default.
• W2893892798 cites W2033023137 @default.
• W2893892798 cites W2073700972 @default.
• W2893892798 cites W2087769239 @default.
• W2893892798 cites W2104175901 @default.
• W2893892798 cites W2108075643 @default.
• W2893892798 cites W2108696783 @default.
• W2893892798 cites W2110217426 @default.
• W2893892798 cites W2114155762 @default.
• W2893892798 cites W2120148259 @default.
• W2893892798 cites W2127359359 @default.
• W2893892798 cites W2138049450 @default.
• W2893892798 cites W2142960568 @default.
• W2893892798 cites W2156584537 @default.
• W2893892798 cites W2157885750 @default.
• W2893892798 cites W2166106092 @default.
• W2893892798 cites W2168958406 @default.
• W2893892798 cites W2265918137 @default.
• W2893892798 cites W2275001939 @default.
• W2893892798 cites W2296970428 @default.
• W2893892798 cites W2312982528 @default.
• W2893892798 cites W2337852073 @default.
• W2893892798 cites W2344869076 @default.
• W2893892798 cites W2615525468 @default.
• W2893892798 cites W4236805817 @default.
• W2893892798 doi "https://doi.org/10.1136/annrheumdis-2018-213150" @default.
• W2893892798 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6241618" @default.
• W2893892798 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30269054" @default.
• W2893892798 hasPublicationYear "2018" @default.
• W2893892798 type Work @default.
• W2893892798 sameAs 2893892798 @default.
• W2893892798 citedByCount "65" @default.
• W2893892798 countsByYear W28938927982018 @default.
• W2893892798 countsByYear W28938927982019 @default.
• W2893892798 countsByYear W28938927982020 @default.
• W2893892798 countsByYear W28938927982021 @default.
• W2893892798 countsByYear W28938927982022 @default.
• W2893892798 countsByYear W28938927982023 @default.
• W2893892798 crossrefType "journal-article" @default.
• W2893892798 hasAuthorship W2893892798A5006567240 @default.
• W2893892798 hasAuthorship W2893892798A5007608312 @default.
• W2893892798 hasAuthorship W2893892798A5009421355 @default.
• W2893892798 hasAuthorship W2893892798A5009557875 @default.
• W2893892798 hasAuthorship W2893892798A5015700716 @default.
• W2893892798 hasAuthorship W2893892798A5021386589 @default.
• W2893892798 hasAuthorship W2893892798A5025765870 @default.
• W2893892798 hasAuthorship W2893892798A5027612338 @default.
• W2893892798 hasAuthorship W2893892798A5029030825 @default.
• W2893892798 hasAuthorship W2893892798A5030599616 @default.
• W2893892798 hasAuthorship W2893892798A5039041675 @default.
• W2893892798 hasAuthorship W2893892798A5040230445 @default.
• W2893892798 hasAuthorship W2893892798A5041199022 @default.
• W2893892798 hasAuthorship W2893892798A5053719643 @default.
• W2893892798 hasAuthorship W2893892798A5053826746 @default.
• W2893892798 hasAuthorship W2893892798A5054508057 @default.
• W2893892798 hasAuthorship W2893892798A5055180780 @default.

• next